ONWARD Medical Raises €40M in Private Placement Led by EQT Life Sciences
Event summary
- ONWARD Medical NV launches a €40M capital increase via a private placement with institutional investors.
- EQT Life Sciences is expected to invest €25M in the offering.
- Proceeds will fund product development, clinical studies, and commercial expansion through Q1 2028.
- Stifel Europe Securities SAS and Bank Degroof Petercam SA/NV act as Joint Bookrunners.
- New shares will be listed on Euronext Brussels, Amsterdam, and Paris on April 20, 2026.
The big picture
ONWARD Medical's €40M capital raise underscores the growing investment in neurotechnology aimed at restoring movement and function in spinal cord injury patients. The participation of EQT Life Sciences signals confidence in the company's proprietary ARC Therapy and its potential to address unmet medical needs. This funding will be critical as ONWARD Medical navigates the competitive landscape of medical device innovation and regulatory approvals.
What we're watching
- Execution Risk
- How ONWARD Medical will allocate the €40M to accelerate product development and commercialization.
- Market Dynamics
- Whether the private placement will enhance ONWARD Medical's competitive position in the neurotechnology sector.
- Strategic Expansion
- The pace at which ONWARD Medical can expand its sales efforts and regulatory activities for the ARC-IM System.
Related topics